lactic acid has been researched along with Neuromuscular Blockade in 3 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Neuromuscular Blockade: The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We included consecutive adult cardiac arrest survivors treated with TTM between 2012 and 2015." | 1.46 | Neuromuscular blockade requirement is associated with good neurologic outcome in cardiac arrest survivors treated with targeted temperature management. ( Cho, YS; Jeung, KW; Jung, YH; Lee, BK; Lee, DH; Min, YI; Youn, CS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Moskowitz, A | 1 |
| Andersen, LW | 1 |
| Rittenberger, JC | 1 |
| Swor, R | 1 |
| Seethala, RR | 1 |
| Kurz, MC | 1 |
| Berg, KM | 1 |
| Chase, M | 1 |
| Cocchi, MN | 1 |
| Grossestreuer, AV | 1 |
| Liu, X | 1 |
| Holmberg, MJ | 1 |
| Callaway, CW | 1 |
| Donnino, MW | 1 |
| Lee, DH | 1 |
| Lee, BK | 2 |
| Jeung, KW | 1 |
| Jung, YH | 1 |
| Cho, YS | 1 |
| Youn, CS | 2 |
| Min, YI | 1 |
| Cho, IS | 1 |
| Oh, JS | 1 |
| Choi, WJ | 1 |
| Wee, JH | 1 |
| Kim, CS | 1 |
| Kim, WY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuromuscular Blockade for Post-Cardiac Arrest Care[NCT02260258] | Phase 2 | 83 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in median serum lactate level between enrollment and 24-hours after the receipt of study drug. A negative number indicates that the lactate levels were lower at 24 hours compared to their level at receipt of study drug. (NCT02260258)
Timeframe: 24 hours
| Intervention | mmol/L (Number) |
|---|---|
| Rocuronium | -2.2 |
| Usual Care | -2.3 |
Interaction between allocated treatment and time: ratio of geometric mean differences over 24 hours in log lactate values between the two groups. (NCT02260258)
Timeframe: 24 hours
| Intervention | Ratio (Number) |
|---|---|
| Effect Estimate | 1.3 |
"Medical Research Council Scale : Measured for 6 muscle groups (3 in the upper limbs and 3 in the lower limbs). Maximum score is 30 (grade 5 for each group) and minimum is 0 (grade 0 for each group). If muscle group strength was not symmetric bilaterally, higher measurement used. Higher scores indicate better outcomes.~Grade 5: Muscle contracts normally against full resistance. Grade 4: Muscle strength is reduced but muscle contraction can still move joint against resistance.~Grade 3: Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed.~Grade 2: Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.~Grade 1: Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle.~Grade 0: No movement is observed" (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days
| Intervention | Points (Median) |
|---|---|
| Rocuronium | 30 |
| Usual Care | 30 |
"Modified Rankin scale to assess neurological outcome at discharge. The scale ranges from 0 to 6, and is used for measuring the performance of daily activities. The score is as follows:~0: No symptoms~1: No significant disability (able to carry out all usual activities, despite some symptoms)~2: Slight disability (able to look after own affairs without assistance, but unable to carry out all previous activities)~3: Moderate disability (requires some help, but able to walk unassisted)~4: Moderately severe disability (unable to attend to own bodily needs without assistance, and unable to walk unassisted)~5: Severe disability (requires constant nursing care and attention, bedridden, incontinent)~6: Dead.~Higher cores represent worse outcomes. Good and bad neurological outcome will be defined as a score of 0-3 and 4-6 respectively. This outcome reports the number of patients with a good neurological outcome( modified Rankin score ≤ 3)" (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rocuronium | 11 |
| Usual Care | 9 |
In-hospital survival (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rocuronium | 14 |
| Usual Care | 14 |
Time from return of spontaneous circulation to target temperature (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days
| Intervention | Hours (Median) |
|---|---|
| Rocuronium | 6.8 |
| Usual Care | 8.3 |
Length of stay in ICU (NCT02260258)
Timeframe: Length of Stay Truncated at 28 Days
| Intervention | days (Median) | |
|---|---|---|
| All patients | ICU survivors | |
| Rocuronium | 6.0 | 9.0 |
| Usual Care | 4.0 | 5.0 |
Mechanical Ventilation Duration in Hours (NCT02260258)
Timeframe: Duration of hospitalization, limit 180 days
| Intervention | Hours (Median) | |
|---|---|---|
| All patients | Survivors to extubation | |
| Rocuronium | 102.0 | 126.3 |
| Usual Care | 82.7 | 66.9 |
2 trials available for lactic acid and Neuromuscular Blockade
| Article | Year |
|---|---|
Continuous Neuromuscular Blockade Following Successful Resuscitation From Cardiac Arrest: A Randomized Trial.
Topics: Aged; Cardiopulmonary Resuscitation; Female; Humans; Hypothermia, Induced; Infusions, Intravenous; L | 2020 |
Continuous neuromuscular blockade infusion for out-of-hospital cardiac arrest patients treated with targeted temperature management: A multicenter randomized controlled trial.
Topics: Aged; Biomarkers; Female; Humans; Hypothermia, Induced; Lactic Acid; Length of Stay; Male; Middle Ag | 2018 |
1 other study available for lactic acid and Neuromuscular Blockade
| Article | Year |
|---|---|
Neuromuscular blockade requirement is associated with good neurologic outcome in cardiac arrest survivors treated with targeted temperature management.
Topics: Adult; Aged; Female; Heart Arrest; Hospital Mortality; Humans; Hypothermia, Induced; Lactic Acid; Mi | 2017 |